The string of clinical failures of agents targeting proteins involved in Aβ production as well as the inability to advance agents targeting tau or tau-phosphorylating kinases argues for the pursuit of alternative strategies for AD therapeutics. This evidence concerns the gene MAPT and Alzheimer disease.